BNET Industries
Last Fiscal Year Sales:$15.3M
- Public
- US
Dow Jones Description
Dyadic International, Inc. is a global biotechnology company with the groundbreaking technology that brings nature to the marketplace. Dyadic is focused on the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms - including humans - found in the earth?s biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, bioenergy, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic?s "one-stop shop" technology rapidly discovers and expresses eukaryotic genes ? the genes of complex living organisms ? and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques, which have limited capabilities to efficiently access the full spectrum of earth's biodiversity. Dyadic?s unique technology virtually ensures that each time a useful gene is discovered, it can also be expressed and then mass-produced. Founded in 1979, Dyadic has significant experience in the discovery, development, manufacturing and commercialization of specialty enzymes and chemicals for the textile, animal feed, and paper and pulp industries. ...
President and Chief Executive Officer
Mark A. EmalfarbNumber of Employees 125
Contact Information
140 Intracoastal Pointe Dr Ste 404
Jupiter, Florida 33477-5904
(561) 743-8333
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
Dyadic International Reports Financial Results for First and Second Quarters of 2009 and Fiscal Years...
-
Dyadic reports results for first time since 2007
-
Cellulase Enzyme Granted GRAS Status
-
Dyadic International Announces Settlement with Securities and Exchange Commission
-
Dyadic International and Abengoa Bioenergy New Technologies Settle Litigation and Ink Licensing Pact
News & Analysis
Filter by
dyadic international inc. - All News and Analysis
Dyadic International, Inc. Announces Changes to Its Board of Directors
JUPITER, Fla. -- Dyadic International, Inc. (the "Company") today announced the election of Mr. Wendell H. Adair, Jr., to the Board of Directors (the "Board") of the Company. Mr. Adair replaces Mr. Richard J. Berman, who has resigned from the Board. On March 14, 2008, the Executive Committee (the...
Berman DeValerio Announces Shareholder Suit Against Dyadic International, Inc.
An investor has sued Dyadic International, Inc. ("Dyadic" or the "Company") (AMEX: DIL) in federal court, accusing the company of securities law violations, Berman DeValerio announced today. Berman DeValerio ( www.bermanesq.com ) filed the class action complaint on November 21, 2007 in the Southern District of Florida. The complaint,...
Dyadic to Present at The BIO CEO & Investor Conference Monday, February 12, 2007, At 11:45 A.M. EST
Webcast Will Be Available At www.dyadic.com JUPITER, Fla. -- Dyadic International, Inc. (Amex:DIL), a global biotechnology company, announced today that CEO Mark Emalfarb will make a presentation to investors at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City, on Monday, February 12, 2007,...
Dyadic to Present at The AMEX First Annual Healthcare Investor Conference Thursday, February 8, 2007, at 10:05 A.M. EST
Webcast Will Be Available at www.dyadic.com JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a global biotechnology company, announced today that CEO Mark Emalfarb will make a presentation to investors at The American Stock Exchange's First Annual Healthcare Investor Conference at the Fairmont Copley Plaza, Boston, on Thursday, February 8,...
Dyadic Closes $13 Million Private Placement
JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that it has closed the previously announced private placement with institutional investors of 2,787,000 shares of common stock and warrants to purchase up to 557,400 shares of common stock for gross proceeds of $13,043,160. The warrants will become...
Dyadic Closes $10 Million R&D and Stock Purchase Agreement with Abengoa Bioenergy in the Area of Cellulosic Ethanol Production
JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that it has closed the previously announced three-year research and development (R&D) agreement and stock purchase agreement with Abengoa Bioenergy R&D, Inc. Abengoa, an Abengoa Bioenergy Company. Under the terms of the stock purchase agreement, Abengoa Bioenergy has...
Pinnacle's Review of Dyadic International Inc.
M2 PRESSWIRE-8 November 2006-Pinnacle Digest: Pinnacle's Review of Dyadic International Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:08112006 Dyadic International Inc. (AMEX:DIL) is a biotechnology company poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived...
Dyadic Granted Patent for High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi
Expands Patent Protection for Dyadic's C1 Host Technology Platform for Applications in Cellulosic Ethanol and Other Key Markets JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that it was granted U.S. patent 7,122,330, "High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi," by the U.S....
Dyadic to Present at the Sanders Morris Harris Investor Growth Conference on October 23, 2006 at 10:00 a.m. EDT
Webcast will be available at www.dyadic.com JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that Mark Emalfarb, Dyadic's President and Chief Executive Officer, will make a presentation at the Sanders Morris Harris Investor Growth Conference to be held in New York City at the Omni...
Dyadic to Present at the ThinkEquity Partners 4th Annual Growth Conference on September 14, 2006 at 11:00 a.m. PDT ; Webcast Will Be Available at www.dyadic.com
JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that Glenn Nedwin, Ph.D, Dyadic's Chief Scientific Officer, Executive Vice President and President of Dyadic's Biosciences Business, will make a presentation at the ThinkEquity Partners 4th Annual Growth Conference to be held at the Ritz Carlton Hotel in...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Mark A. Emalfarb | President and Chief Executive Officer |
| Charles W Kling | Senior Vice President, Sales & Marketing |
| Daniel Michalopoulos | Senior Vice President, R & D |
| Ratnesh Chandra | Senior Vice President, Marketing, Biotechnology Systems |
| Ray Chandra | Senior Vice President, Marketing |
| Richard J. Berman | Professional Director |
| Arkady P Sinitsyn | Head of Laboratory, Moscow State University |
| Carlos Barbas | Professor, the Scripps Research Institute |
| Peter J. Punt | Staff Scientist |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Robert B Shapiro | Board of Directors |
| Seth J Herbst | Board of Directors |
| Stephen J Warner | Board of Directors |
| Wayne Moor | Board of Directors |
| Wendell H. Adair | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | President and Chief Executive Officer | Current |
| Dyadic International, Inc. | Owner | Current |
| Dyadic International, Inc. | Chairman | Current |
| The University of Iowa | B.A. Degree | Former |
Charles W. Kling IV has been our Vice President, Sales, Enzymes since January 2007. Prior to that he served as our Vice President of Sales and Marketing - Enzymes from July 2005 through December 2006. Prior to joining us, Mr. Kling served as Group Manager of Hercules, Inc.'s Pulp & Paper division, with full P&L responsibility and management of staff of over 60 people, from 1998 to 2005. Prior to Hercules, from 1990 to 1998, Mr. Kling served as Global Director, Technical Marketing for BetzDearborn Inc.'s Pulp & Paper division. From 1986 to 1990, he was Division Manager, S.D. Warren division of Scott Paper. Prior to that, he served as Production Manager for Buckeye Cellulose, a division of Proctor and Gamble, Inc. Mr. Kling received his B.S. degree in Civil Engineering from University of Alabama.
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Senior Vice President, Sales & Marketing | Current |
| Enzymes Inc. | Vice President, Sales | Current |
| Hercules Incorporated | Group Manager | Former |
| The University of Alabama | B.S. Degree In Civil Engineering | Former |
Daniel Michalopoulos, Ph.D . has been our Vice President, Marketing, Enzymes since January 2007. Prior to that he served as our Vice President, Pulp & Paper from February 2005 through December 2006 and is focused on growing our pulp and paper effort. Prior to joining us, he served as Senior Program Manager for Hercules' Pulp and Paper Division from 1998 to 2005 where he managed a staff of 40 people with an annual budget of $8 million. Prior to that, he served as Research Director at BetzDearborn Pulp and Paper Division and held other research and management positions at Betz PaperChem. Dr. Michalopoulos conducted his post-doctoral work at Rice University, received his Ph.D. in Chemistry from Colorado State University and his B.S. in Chemistry from Lowell Technological Institute.
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Senior Vice President, R & D | Current |
| Enzymes Inc. | Vice President, Marketing | Current |
| Colorado State University | Ph.D. In Chemistry | Former |
| Lowell Technological Institute | B.S. In Chemistry | Former |
| Rice University | Postdoctoral | Former |
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Senior Vice President, Marketing, Biotechnology Systems | Current |
| Schering-Plough Corporation | Former | |
| Genencor | Former | |
| New York University | M.B.A. | Former |
| Columbia University | M.S. In Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Senior Vice President, Marketing | Current |
| Schering-Plough Corporation | Former | |
| Merck & Co. Inc. | Former | |
| Genencor International, Inc. | Former | |
| New York University | M.B.A. | Former |
| Columbia University | M.S. in engineering | Former |
Richard J. Berman was elected by the Board to serve as its non-executive Chairman in June 2007, having served as C.E.O. of the Company from January 2006-June 2007, and on the Board of Directors since 2002. Since 2001, Mr. Berman has served as a Director and/or Chairman of several public and private companies. Mr. Berman currently serves as Chairman of National Investment Managers, a public company in pension administration and investment management; Chairman of Candidate Resources, a private company delivering HR services over the web, and Chairman of Fortress Technology Systems (homeland security). Mr. Berman is a director of eight public companies: Dyadic International, Inc. (AMEX: DIL), Broadcaster, Inc. (OTC: BCSR.OB), Internet Commerce Corporation (Nasdaq: ICCA), MediaBay, Inc. (Nasdaq: MBAY), NexMed, Inc., National Investment Managers (OTC: NIVM.OB), Advaxis, Inc. (OTC: ADXS.OB), and NeoStem, Inc (OTC:NEOI.OB). He is a past Director of the Stern School of Business of NYU, where he obtained his BS and MBA. He has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.
| Organization | Position | Status |
|---|---|---|
| NexMed, Inc. | Chief Executive Officer | Current |
| Morlex Inc Co | CEO | Current |
| EB2B Commerence, Inc | Chairman and Chief Executive Officer | Current |
| Dyadic International, Inc. | Professional Director | Current |
| MediaBay, Inc. | Professional Director | Current |
| Broadcaster, Inc. | Professional Director | Current |
| Gvi Security Solutions, Inc. | Professional Director | Current |
| Morlex Inc Co | National Investment Managers | Current |
| Internet Commerce Corporation | Distributor | Current |
| Bion Technologies, Inc | All Executive | Current |
| Turboproject | Current | |
| Bion Dairy Corporation | Current | |
| Morlex Inc Co | Chairman | Current |
| National Investment Managers, Inc. | Chairman | Current |
| Neostem, Inc. | Chairman | Current |
| Duncan Capital Partners LLC | Chairman | Current |
| Dyadic International, Inc. | Chairman | Current |
| Secure Fortress Plc | Chairman | Current |
| Superfly Advertising | Executive Chairman | Current |
| Broadcaster, Inc. | Board of Directors | Current |
| Int, Inc. | Board of Directors | Current |
| Advaxis, Inc. | Director | Current |
| Imsi | Board of Directors | Current |
| Gvi Security Solutions, Inc. | Board of Directors | Current |
| Hijaak | Board of Directors | Current |
| Internet Commerce Corporation | C.E.O | Former |
| NexMed, Inc. | President & Chief Executive | Former |
| Bankers Trust Company Inc. | Senior Vice President | Former |
| New York University | past Director | Former |
| NexMed, Inc. | Professional Director | Former |
| NexMed, Inc. | Director | Former |
| New York University | Director | Former |
| Dyadic International, Inc. | Director | Former |
| Neostem, Inc. | Director | Former |
| Boston College Law School | J.D. | Former |
| Boston College | Degrees | Former |
Dr. Sinitsyn is a member of the Russian National Research Program on Enzyme Engineering Council. He has co-authored 270 publications in Russian and international scientific journals, as well as more than 20 Russian and three international patents. Dr. Sinitsyn received his Ph.D. in Enzymology and Dr. of Sciences in Enzymology and Biochemistry from Moscow State University.
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Head of Laboratory, Moscow State University | Current |
| Moscow State University | Sciences | Former |
Dr. Barbas is a Professor of The Scripps Research Institute, Departments of Molecular Biology and Chemistry and The Skaggs Institute for Chemical Biology. He holds the Janet and W. Keith Kellogg II endowed Chair in Molecular Biology and Chemistry. Dr. Barbas has received honours including the Investigator Award from the Cancer Research Institute, The Scholar Award of the American Foundation for AIDS Research, and the Presidential Green Chemistry Challenge Award. He is the author of over 200 scientific articles and is a named inventor on 32 issued U.S. patents. Key accomplishments in the area of biotechnology pioneered by Dr. Barbas and his colleagues include the development of the first human antibody phage libraries, development of the first synthetic antibodies, the development of the first artificial transcription factors capable of regulating endogenous genes, and chemically programmed antibodies-the CovX core technology. Dr. Barbas received his Ph.D. in Organic Chemistry from Texas A&M University.
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Professor, the Scripps Research Institute | Current |
| The Scripps Research Institute | Professor | Current |
| Covx Research LLC | Board of Directors | Current |
| Texas A&M University | PhD In Organic Chemistry | Former |
Dr. Peter J. Punt has been a staff scientist in molecular genetics at TNO Nutrition and Food Research Institute in the Netherlands since 1983. He has worked at TNO as a project leader since 1992 - and more recently as workgroup leader - in the department of Applied Microbiology and Gene Technology. Dr. Punt has co-authored more than 40 peer-reviewed scientific papers and three published patents. Dr. Punt obtained his M.Sc. in Biology from Leiden University in 1984, and his Ph.D. in Molecular Genetics from Amsterdam University in 1992. Head of Laboratory, Department of Enzymology, Moscow State University, Moscow, Russia Dr. Sinitsyn has worked with Moscow State University since 1974, first as a researcher, then as a senior researcher, and most recently as the head of its Laboratory of Physical Chemistry of Enzymatic Transformation of Polymers. His scientific expertise includes enzymology, biochemistry, microbiology, and genetics of carbohydrases (cellulases and xylanases), proteases, lipases, esterases, and other enzymes for application in textiles and detergents, pulp and paper, food and animal feed, and other industrial uses.
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Staff Scientist | Current |
| Moscow State University | Researcher | Former |
| Leiden University | Ph.D. In Molecular Genetics from Amsterdam University | Former |
| Organization | Position | Status |
|---|---|---|
| Morgan Street Document Systems | Co-Founder of Morgan Street | Current |
| Westbury Partners | Current | |
| Westbury Equity Partners SBIC, L.P. | Advisory Member | Current |
| Northwestern Memorial Hospital | Director | Current |
| Theranos, Inc | Board of Directors | Current |
| The Center for Contemplative Mind In Society | Board of Directors | Current |
| Morgan Street Document Systems | Board of Directors | Current |
| Dyadic International, Inc. | Board of Directors | Current |
| The Business Council | Board of Directors | Current |
| Darkstrand, Inc. | Board of Directors | Current |
| American Society | Board of Directors | Current |
| The Business Council | Member | Current |
| Monsanto Company | Chief Executive Officer | Former |
| Pharmacia Corporation | CEO | Former |
| Pharmacia Corporation | Chief Operating Officer | Former |
| General Instrument Corporation | Vice President | Former |
| General Instrument Corporation | General Counsel | Former |
| Monsanto Company | Head | Former |
| Pharmacia Corporation | Chairman | Former |
| Monsanto Company | Chairman | Former |
| Rockwell International Corporation | Director | Former |
| SEQUUS Pharmaceuticals | Director | Former |
| Harvard College | Former |
| Organization | Position | Status |
|---|---|---|
| Visions Clinical Research | Director of Surgical Studies | Current |
| Dyadic International, Inc. | Board of Directors | Current |
| Visions Clinical Research | Board Certified Obstetrician, Gynecologist | Former |
| Organization | Position | Status |
|---|---|---|
| Rock Energy Resources, Inc. | Co-Founder | Current |
| Crossbow Ventures, Inc. | Chairman | Current |
| Redchip Companies, Inc. | Director | Current |
| Maxim Tep, Inc | Director | Current |
| Rock Energy Resources, Inc. | Board of Directors | Current |
| Uct Coatings, Inc. | Board of Directors | Current |
| Dyadic International, Inc. | Board of Directors | Current |
| Aoi Medical, Inc. | Board of Directors | Current |
| Commonwealth Associates, Inc. | Managing Director | Former |
| International Development | Consultant | Former |
| USAID | Consultant | Former |
| Wharton Graduate School of the University of Pennsylvania | MBA | Former |
| The Wharton School of the University of Pennsylvania | Master of Business Administration | Former |
| Massachusetts Institute of Technology | Bachelor of Science degree | Former |
| Blackstone Corporation | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Board of Directors | Current |
| Dyadic International, Inc. | Interim CEO & President | Former |
| Boca Resorts, Inc. | Chief Financial Officer | Former |
| Boca Resorts, Inc. | Senior Vice President | Former |
| Boca Resorts, Inc. | Treasurer | Former |
| University of Montevallo | Undergraduate Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Dyadic International, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
-
Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about MNTA
-
Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about EBS
-
Targacept, Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about TRGT
-
Nabi Biopharmaceuticals Q3 2009 Earnings Call Transcript
on Nov 05, 2009about NABI
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Merck KGaA on Cancer Vaccines: We're Not Crazy, Just Convinced 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

